+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Integrin Beta 1"

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2019 - Product Thumbnail Image

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2019

  • Drug Pipelines
  • April 2019
  • 75 Pages
  • Global
From
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018 - Product Thumbnail Image

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018

  • Drug Pipelines
  • November 2018
  • 86 Pages
  • Global
From
Cells Expressing Integrin Beta 3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cells Expressing Integrin Beta 3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 36 Pages
  • Global
From
Integrin Beta 3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Integrin Beta 3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 57 Pages
  • Global
From
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H2 2018 - Product Thumbnail Image

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H2 2018

  • Drug Pipelines
  • November 2018
  • 57 Pages
  • Global
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Integrin Beta 1 (ITGB1) is a protein found on the surface of cells that plays a role in cell adhesion and migration. In oncology, ITGB1 is a target for drug development, as it is involved in the growth and spread of cancer cells. ITGB1 inhibitors are being developed to block the activity of ITGB1, thus preventing cancer cells from growing and spreading. ITGB1 inhibitors are being studied in a variety of cancer types, including breast, lung, and colorectal cancer. In addition, ITGB1 inhibitors are being studied in combination with other therapies, such as chemotherapy and immunotherapy, to improve the efficacy of treatment. Several companies are developing ITGB1 inhibitors for the treatment of cancer. These include AstraZeneca, Merck, Pfizer, Novartis, and Bristol-Myers Squibb. Show Less Read more